ArticleBMC cardiovascular disorders2025
Fluoroquinolone use and aortic aneurysm or dissection: a German cohort study based on nationwide SHI-physicians outpatient claims data confirms increased risk.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute aortic dissection (AAD) is a potentially life-threatening condition with an annual incidence of approximately 6.0–16.9 per 100,000 inhabitants. Fluoroquinolone use has been identified as a potential risk factor for aortic aneurysm/acute aortic dissection (AA/AAD), leading to restrictions on their clinical indication. As adverse drug reactions (ADRs) are a key issue in pharmacovigilance, this study addresses two questions: First, can the reported association between fluoroquinolones and AA/AAD be confirmed in German routine healthcare data? Second, is there an association with the risk of AA/AAD, considering the role of underlying infections?
methodsWe analyzed prescription and diagnostic data of statutory health insurance patients in Germany (~ 87% of the population) between 2009 and 2017. Patients treated with fluoroquinolones were compared with a propensity score-matched control group treated with other non-fluoroquinolone antibiotics. Cox proportional hazards models were used to estimate hazard ratios (HRs) for aortic aneurysm and dissection. Graph-theoretic methods were applied to identify morbidity-related variables for propensity score matching.
resultsPatients treated with fluoroquinolones had a higher risk of developing AA/AAD compared to those treated with other antibiotics (HR: 1.56). In sensitivity analyses excluding patients with pneumonia or aortic dissection, the risk was slightly reduced (HR: 1.43). The HR remained elevated even when adjusted for underlying infections, sex and age (HR: 1.48), indicating a potential drug-related effect independent of specific infections.
conclusionsFluoroquinolone use is associated with an increased risk of aortic aneurysm and dissection. These findings highlight the value of routine healthcare data in detecting adverse drug reactions and underline the need for careful risk–benefit evaluation when prescribing fluoroquinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.